SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Exercise of Restricted Stock Units 
 
   Oxford, UK, and Cambridge, MA, US, 27 January 2020 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism 
antibiotic innovation, announces that following the exercise of 
restricted stock units by former directors, the Company has issued 
269,230 new ordinary shares of one penny each (the "New Ordinary 
Shares"). 
 
   Application has been made for the admission to trading on AIM of the New 
Ordinary Shares, which will rank pari passu with the Company's existing 
ordinary shares, and admission is expected to occur on or around 30 
January 2020. 
 
   Following admission of the New Ordinary Shares to trading on AIM, the 
total number of ordinary shares with voting rights in issue will be 
336,159,511. This figure may be used by shareholders as the denominator 
for the calculations by which they will determine if they are required 
to notify their interest in, or a change to their interest in, the 
Company under the FCA's Disclosure and Transparency Rules. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, Enterobacteriaceae and N. gonorrhoeae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)              Tel:    44 (0)1235 443 951 
Michelle Avery (US office)                                     +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated Adviser)    Tel:   +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

January 27, 2020 02:00 ET (07:00 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Dec 2024 to Jan 2025

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Jan 2024 to Jan 2025